Sean P. Lyden

Sean P. Lyden

Auto-generated profile, based on publicly available information

Sean P. Lyden

Department of Vascular Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
ETEric J. Turney
Eric J. Turney
SSSean P. Steenberge
Sean P. Steenberge
SLSean P. Lyden
Sean P. Lyden
MEMatthew J. Eagleton
Matthew J. Eagleton
SSSunita D. Srivastava
Sunita D. Srivastava
DCDaniel G. Clair
Daniel G. Clair

2 May 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CMCraig N. Morrell
Craig N. Morrell
DMDoran Mix
Doran Mix
AAAnu Aggarwal
Anu Aggarwal
RBRohan Bhandari
Rohan Bhandari
MGMatthew Godwin
Matthew Godwin
SCScott J Cameron
Scott J Cameron
As blood transitions from steady laminar flow (S-flow) in healthy arteries to disturbed flow (D-flow) in aneurysmal arteries, platelets are subjected to external forces. Biomechanical platelet activation is incompletely understood and is a potential mechanism behind antiplatelet medication resistance. Although it has been demonstrated that antiplatelet drugs suppress the growth of abdominal aortic aneurysms (AAA) in patients, we found that a certain degree of platelet reactivity persisted in spite of aspirin therapy, urging us to consider additional antiplatelet therapeutic targets. Transcriptomic profiling of platelets from patients with AAA revealed upregulation of a signal transduction pathway common to olfactory receptors, and this was explored as a mediator of AAA progression. Healthy platelets subjected to D-flow ex vivo, platelets from patients with AAA, and platelets in murine models of AAA demonstrated increased membrane olfactory receptor 2L13 (OR2L13) expression. A drug screen identified a molecule activating platelet OR2L13, which limited both biochemical and biomechanical platelet activation as well as AAA growth. This observation was further supported by selective deletion of the OR2L13 ortholog in a murine model of AAA that accelerated aortic aneurysm growth and rupture. These studies revealed that olfactory receptors regulate platelet activation in AAA and aneurysmal progression through platelet-derived mediators of aortic remodeling.

7 November 2023 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
KPKosmas I. Paraskevas
Kosmas I. Paraskevas
MBMartin M. Brown
Martin M. Brown
BLBrajesh K. Lal
Brajesh K. Lal
Piotr MyrchaPiotr Myrcha
Piotr Myrcha
SLSean P. Lyden
Sean P. Lyden
AAAli F. AbuRahma
Ali F. AbuRahma

1 January 2020 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
CHCollin Haben
Collin Haben
WPWoosup M. Park
Woosup M. Park
JBJames Bena
James Bena
FPF. Ezequiel Parodi
F. Ezequiel Parodi
SLSean P. Lyden
Sean P. Lyden

17 October 2024 in Blood
Verified
Journal Article
Closed access
TBTyler W. Benson
Tyler W. Benson
MPMindy M. Pike
Mindy M. Pike
ASAnthony Spuzzillo
Anthony Spuzzillo
SHSarah M. Hicks
Sarah M. Hicks
SASidra Ali
Sidra Ali
AOA. Phillip Owens
A. Phillip Owens
A common feature in patients with abdominal aortic aneurysms (AAAs) is the formation of a nonocclusive intraluminal thrombus (ILT) in regions of aortic dilation. Platelets are known to maintain hemostasis and propagate thrombosis through several redundant activation mechanisms, yet the role of platelet activation in the pathogenesis of AAA-associated ILT is still poorly understood. Thus, we sought to investigate how platelet activation affects the pathogenesis of AAA. Using RNA sequencing, we identified that the platelet-associated transcripts are significantly enriched in the ILT compared with the adjacent aneurysm wall and healthy control aortas. We found that the platelet-specific receptor glycoprotein VI (GPVI) is among the top enriched genes in AAA ILT and is increased on the platelet surface of patients with AAAs. Examination of a specific indicator of platelet activity, soluble GPVI (sGPVI), in 2 independent cohorts of patients with AAAs is highly predictive of an AAA diagnosis and associates more strongly with aneurysm growth rate than D-dimer in humans. Finally, intervention with the anti-GPVI antibody (JAQ1) in mice with established aneurysms blunted the progression of AAA in 2 independent mouse models. In conclusion, we show that the levels of sGPVI in humans can predict a diagnosis of AAA and AAA growth rate, which may be critical in the identification of high-risk patients. We also identify GPVI as a novel platelet-specific AAA therapeutic target, with minimal risk of adverse bleeding complications, for which none currently exists.

15 February 2024 in Journal of Vascular Surgery
Verified
Journal Article
Open access
SLSean P. Lyden
Sean P. Lyden
PSPeter A. Soukas
Peter A. Soukas
ADAjanta De
Ajanta De
BTBarry Tedder
Barry Tedder
JBJonathan Bowman
Jonathan Bowman
EAEhrin J. Armstrong
Ehrin J. Armstrong
Percutaneous transmural arterial bypass (PTAB) using the DETOUR system aims to create a percutaneous, endovascular femoropopliteal bypass for the treatment of long segment, complex superficial femoral and proximal popliteal artery disease. The goal of the DETOUR2 study is to investigate the safety and effectiveness of the therapy in comparison with pre-established performance goals. The DETOUR2 investigational device exemption study is a prospective, single-arm, multicenter, international trial of symptomatic peripheral arterial disease patients (Rutherford classes 3-5) undergoing the DETOUR procedure for long segment (>20 cm) superficial femoral artery disease. Prespecified end points included primary safety (composite of major adverse events) at 30 days, and effectiveness (primary patency defined as freedom from restenosis or clinically driven target lesion revascularization) at 1 year. We enrolled 202 patients at 32 sites with 200 treated with the DETOUR system. The mean lesion length was 32.7 cm, of which 96% were chronic total occlusions (CTO) and 70% were severely calcified. Technical success was achieved in 100% of treated patients. The primary safety end point was met with a 30-day freedom from major adverse event rate of 93.0%. The 1-year primary effectiveness end point was met with 72.1% primary patency at 12 months. Primary-assisted and secondary patency were 77.7% and 89.0%, respectively, at 12 months. The 12 month deep venous thrombosis incidence was 4.1% with no pulmonary emboli reported. Venous quality-of-life scores showed no significant changes from baseline. There was a Rutherford improvement of at least one class through 12 months in 97.2% of patients. The mean ankle-brachial index also improved from 0.61 to 0.95 during this period. There were marked improvements in quality-of-life and functional status measures. The DETOUR2 study met both the primary safety and effectiveness end points, demonstrating clinical usefulness of this novel therapeutic strategy in long femoropopliteal lesions.